Apexigen Apx005m-006- A Phase 2 Study Of Apx005m In Combination With Concurrent Chemoradiation As Neoadjuvant Therapy For Resectable Esophageal And Gastroesophageal Junction Cancers
Posted Date: Sep 4, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Esophageal Diseases, Oncology
- Type of Study: Drug
This pilot phase II trial studies the side effects of CD40 agonistic monoclonal antibody APX005M (APX005M), chemotherapy, and radiation therapy, and to see how well they work when given before surgery in treating patients with esophageal cancer or gastroesophageal cancer that can be removed by surgery. The primary outcome of this study is pathologic complete response rate.
Criteria:
To Be Eligible: Must Have Diagnosis Of Surgically Resectable Squamous Cell Carcinoma, Adenocarcinoma Or Undifferentiated Carcinoma Of The Esophagus Or Ge Junction, Ecog 0-1, No Other Malignancy Within 1 Year, No Prior Treatment For Current Study Cancer, No Significant Medical History That Could Impact Study Treatment, No History Of Hypersensitivity Monoclonal Antibodies Or Immunoglobulin G
Keywords:
Esophageal Cancer, Gastroesophageal Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com